Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the te... PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug discovery platform that integrates the technologies to synthesize highly diverse macrocyclic peptide libraries and screen for hit compounds, as well as enables rapid and efficient identification of novel hit compounds with high potency and selectivity for protein targets in drug discovery campaigns. It is developing 64Cu-ATSM indicated for malignant brain tumor; and 177Lu/64Cu-PSMA I&T indicated for prostate cancer that are in phase 3 clinical phase development stage, as well as GhR Antagonist indicated for acromegaly that is in phase 2 clinical phase development stage. The company also develops 225Ac/68Ga-GPC3 indicated for hepatocellular carcinoma; 177Lu/68Ga-FAP indicated for pancreatic, lung, breast, colon cancer; 225Ac/64Cu-CA9 indicated for renal cell carcinoma; 18F-PD-L1 indicated for cancer; CD38-ARM indicated for multiple myeloma; S2-protein inhibitors indicated for COVID-19; and merck that are in phase 1 clinical phase development stage. In addition, it develops novartis and rayzeBio indicated for cancer, 225Ac/64Cu-CLDN18.2 indicated for stomach cancer, 225Ac/177Lu/64Cu/68Ga-CDH3 indicated for head and neck cancer, KIT inhibitors indicated for allergic diseases, oral myostatin inhibitors indicated for obesity/muscle disease, and Oral IL-17A/F inhibitors indicated for inflammatory diseases such as psoriasis that are currently under preclinical development stage. Further, the company involved in research, development, manufacture and sale of pharmaceuticals in the fields of radiopharmaceuticals (RI) and non-RI. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan. Mehr anzeigen
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.6 | -9.09090909091 | 6.6 | 6.6 | 5.98 | 300 | 5.98 | CS |
| 4 | -1.02 | -14.5299145299 | 7.02 | 7.31 | 5.98 | 614 | 6.91249253 | CS |
| 12 | -1.75 | -22.5806451613 | 7.75 | 8.255 | 5.98 | 955 | 7.67375253 | CS |
| 26 | -6.19 | -50.7793273175 | 12.19 | 12.85 | 5.98 | 645 | 8.27600504 | CS |
| 52 | -7.53 | -55.6541019956 | 13.53 | 13.53 | 5.98 | 652 | 9.75970778 | CS |
| 156 | -6.402 | -51.6207063377 | 12.402 | 18 | 5.98 | 730 | 12.01101506 | CS |
| 260 | -42.8052 | -87.7062280249 | 48.8052 | 48.8052 | 5.98 | 970 | 17.1377301 | CS |
Trades verzögert
Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto
Auf Echtzeit aktualisieren| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
